Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd held its 22nd Annual General Meeting (AGM) on August 29, 2026, where the company presented its financial performance for FY 2025-26. The company's revenue and profit before tax increased, and earnings per share improved. The company also discussed its business model, operational focus, and priorities for FY 2026-27.

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Swapan Khandelwal.

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, stating that Mr. Swapan Khandelwal, a promoter and whole-time director, has acquired 78,000 equity shares representing 0.81% of the total issued and paid-up share capital through the open market.

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd has published a notice in newspapers for its 22nd Annual General Meeting (AGM) and e-voting, as per SEBI regulations.

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd has announced the record date for remote e-voting in relation to its 22nd Annual General Meeting scheduled for August 29, 2026.

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd has announced that its share transfer books and register of members will be closed from August 23rd to August 29th, 2026, for the purpose of its 22nd Annual General Meeting on August 29th, 2026.

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd submitted its Annual Report for FY 2025-26, including a notice convening its 22nd Annual General Meeting. The company operates in various states in India, focusing on quality therapeutic brands and customer satisfaction. It has over 20 years of experience and is expanding its business.

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd has announced the notice of its 22nd Annual General Meeting (AGM) to be held on August 29, 2026, at Hotel Airport Centre Point, Nagpur. The AGM will consider the adoption of audited financial statements, declaration of dividend on preference shares, re-appointment of a director, and approval of related party transactions with Activista Healthcare Private Limited and Nucleage Pharma Solutions Private Limited.

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd has received a disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011, regarding the acquisition of 27000 equity shares by Mr. Prashant Shrikrishna Karkare, Executive Director, through the open market.

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd announced that its Promoter and Whole Time Director, Mr. Swapan Khandelwal, acquired 60,000 equity shares, representing 0.62% of the total paid-up share capital, through open market purchases on June 22, 2026. This disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.